RELMADA THERAPEUTICS INC (RLMD) Stock Analyst Ratings
NASDAQ:RLMD - Nasdaq - US75955J4022 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 48% to RLMD. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 0.88. This target is 199.67% above the current price.
RLMD was analyzed by 8 analysts. The buy percentage consensus is at 48. So analysts seem to be rather neutral about RLMD.
In the previous month the buy percentage consensus was at a similar level.
RLMD was analyzed by 8 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-12-05 | Mizuho | Downgrade | Outperform -> Neutral |
| 2024-12-04 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2024-09-17 | Jefferies | Upgrade | Hold -> Buy |
| 2024-06-05 | Goldman Sachs | Downgrade | Neutral -> Sell |
| 2023-06-15 | Mizuho | Reiterate | Buy -> Buy |
| 2023-01-23 | SVB Leerink | Maintains | Outperform |
| 2022-10-14 | Guggenheim | Downgrade | Buy -> Neutral |
| 2022-10-14 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2022-10-13 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2022-09-23 | Goldman Sachs | Maintains | Buy |
| 2022-09-06 | Guggenheim | Maintains | Buy |
| 2022-05-09 | Oppenheimer | Maintains | Outperform |
| 2021-12-20 | SVB Leerink | Maintains | Outperform |
| 2021-11-18 | Mizuho | Initiate | Buy |